已收盤 12-24 16:00:00 美东时间
-0.060
-1.10%
今日重点评级关注:摩根士丹利:维持Kyverna Therapeutics"超配"评级,目标价从20美元升至25美元;Maxim Group:维持Capricor Therapeutics"买入"评级,目标价从25美元升至50美元
12-05 08:35
JP Morgan analyst Richard Shane maintains Oportun Financial (NASDAQ:OPRT) with a Underweight and lowers the price target from $6 to $5.5.
12-05 01:43
Oportun Financial shares are trading higher after the company reported Q3 resul...
11-05 06:00
Financial Outlook for Fourth Quarter and Full Year 2025 Oportun is providing the following guidance for 4Q 2025 and full year 2025 as follows: 4Q 2025Full Year 2025Total Revenue$241 - $246M$950 -
11-05 05:23
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Oportun will release its third-quarter 2025 financial results on November 4, 2025, after market close. A conference call and earnings webcast to discuss the results will be held at 5:00 pm ET / 2:00 pm PT on the same day. The webcast can be accessed at investor.oportun.com, with a replay available for one year. The dial-in numbers for the call are 1-866-604-1698 (toll-free) and 1-201-389-0844 (international). Participants are advised to dial in 1...
10-21 20:10
Oportun issued $441 million in two-year revolving fixed rate asset-backed notes secured by installment loans. The offering included five classes of fixed rate notes rated by Fitch from AAA to BB-. The weighted average yield was 5.77%, with Class A notes at 4.53% and Class E at 10.82%. This is Oportun's fourth ABS transaction of the year and third consecutive AAA rating, reflecting strong investor demand and access to low-cost funding.
10-20 12:00
Oportun Financial: 12-Month Extension of an Existing Warehouse Facility With Go...
10-15 04:11
Oportun has enhanced its debt capital structure by adding a $247 million warehouse facility with Citizens Financial Group and Community Investment Management, extending an existing facility with Goldman Sachs and Jefferies for 12 months, increasing the weighted average remaining term of facilities from 17 to 25 months, and proactively paying down $17.5 million in higher cost corporate debt, totaling $50 million since October 2024.
10-14 20:10
今日重点评级关注:Maxim Group:维持Gain Therapeutics"买入"评级,目标价从5美元升至7美元;HC Wainwright & Co.:维持Icecure Medical"买入"评级,目标价从2美元升至2.5美元
10-08 09:14